Alopecia and Atopic Dermatitis: Pathogenesis, Comorbidities, and Precision Management
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: 20 September 2026 | Viewed by 25
Special Issue Editors
Interests: dermatology; atopic dermatitis; biomarkers; skin barrier
Special Issues, Collections and Topics in MDPI journals
Interests: psoriasis; alopecia; atopic dermatitis
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Alopecia and atopic dermatitis (AD) are chronic, highly heterogeneous inflammatory disorders with substantial psychosocial burden and frequent overlap in immune dysregulation, barrier dysfunction, and comorbidity patterns. Despite rapid therapeutic progress, key gaps remain: defining clinically meaningful endotypes, identifying actionable biomarkers for diagnosis and treatment response, clarifying shared and distinct pathogenic pathways (including type 2 and non-type 2 inflammation), and generating real-world evidence to optimize long-term, personalized management. This Special Issue aims to synthesize current knowledge and accelerate translation into practice. We welcome original research, reviews, and clinically focused perspectives addressing immune pathways and endotypes, skin barrier and inflammation, comorbidities and quality of life, biomarkers and treatment response, advanced therapies (biologics/JAK inhibitors), and real-world outcomes. By bringing clinical investigators, this collection will help refine precision strategies and improve patient-centered care.
Dr. Trinidad Montero-Vilchez
Prof. Dr. Salvador Arias-Santiago
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- alopecia
- atopic dermatitis
- comorbidities
- immune dysregulation
- barrier dysfunction
- precision management
- diagnosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
